Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-09-13 Proxy Solicitation & In…
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
S-4/A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an Amendment No. 2 to Form S-4 registration statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. The text includes a proxy statement/prospectus related to a merger between Abbott Laboratories and St. Jude Medical, describing the merger agreement, shareholder voting proposals, and related merger details. It is not a financial report, earnings release, or annual report, but rather a detailed solicitation of shareholder votes on merger proposals and related corporate governance matters. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, especially in the context of mergers. The document is lengthy (15,000 characters) and contains substantive merger and voting information, not just an announcement or summary. Therefore, the correct classification is PSI with high confidence.
2016-09-13 English
Abbott Laboratories Files Amendment to Form S-4
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed proxy statement/prospectus filed with the SEC related to a merger transaction between Abbott Laboratories and St. Jude Medical, Inc. It includes a notice of an annual meeting of shareholders, proposals to be voted on including approval of the merger agreement, election of directors, and other shareholder matters. The document references the Agreement and Plan of Merger and contains detailed information about the merger consideration, voting instructions, and recommendations from the board of directors. The presence of a proxy statement/prospectus related to a merger and the solicitation of shareholder votes on merger proposals clearly identifies this as a Proxy Solicitation & Information Statement. It is not an annual report, earnings release, or other financial report, but rather a document sent to shareholders to provide information and request votes for the meeting concerning the merger and related proposals.
2016-09-13 English
425 Filing
Call Transcript Classification · 95% confidence The document is an edited transcript of a conference call involving Abbott Laboratories and Wells Fargo Securities Healthcare Conference. It includes detailed discussions on the St. Jude Medical acquisition, integration progress, financial considerations such as debt-to-EBITDA ratios, synergy expectations, and capital allocation priorities. The presence of multiple speakers, Q&A format, and detailed financial and strategic commentary are characteristic of a call transcript. The document is not a brief announcement, proxy statement, or regulatory filing, nor is it a formal report like an annual or quarterly report. Therefore, the document fits the category of a Call Transcript (CT). The length of the document (about 15,000 characters) and the detailed content support this classification with high confidence.
2016-09-08 English
Abbott Laboratories Files Rule 425 Document
Call Transcript Classification · 95% confidence The document is a full transcript of a conference call involving Abbott Laboratories, specifically at the Wells Fargo Securities Healthcare Conference. It includes detailed discussions on the St. Jude Medical acquisition, capital allocation, synergy expectations, and integration progress. The presence of multiple speakers, Q&A format, and detailed financial and strategic commentary are characteristic of an earnings or investor conference call transcript. The document also references forward-looking statements and SEC filings but is itself a transcript, not a report or announcement. Therefore, it fits the definition of a Call Transcript (CT). The document length (over 14,000 characters) and content confirm it is not a brief announcement or a report publication notice. Hence, the classification is CT with high confidence.
2016-09-08 English
Regulatory Filings 2016
Regulatory Filings
2016-09-06 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-4 filed by Abbott Laboratories. The Form S-4 is used for securities registration in connection with mergers and acquisitions. The letter discusses amendments to the Registration Statement, financial analyses, risk factors, merger agreements, and other merger-related disclosures. It is not the registration statement itself but a correspondence related to the filing and review process. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory correspondence and does not contain the actual merger filing or financial statements but responses to SEC comments on the filing.
2016-08-09 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.